Imetelstat sodium, developed by Geron Corporation, is positioned to address a significant unmet need in the treatment of transfusion-dependent patients with low or intermediate-1 risk MDS who are relapsed/refractory to erythropoiesis-stimulating agents (ESAs). The market for MDS therapies is growing, with increasing demand for effective treatments that can improve transfusion independence and overall survival. Competitive landscape includes hypomethylating agents and other novel therapies, but imetelstat's unique mechanism may provide a differentiated offering. Diligence should focus on the robustness of clinical data, potential regulatory pathways, and the landscape of ongoing and upcoming clinical trials in MDS.